» Articles » PMID: 32581723

Sialylation and Galectin-3 in Microglia-Mediated Neuroinflammation and Neurodegeneration

Overview
Specialty Cell Biology
Date 2020 Jun 26
PMID 32581723
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Microglia are brain macrophages that mediate neuroinflammation and contribute to and protect against neurodegeneration. The terminal sugar residue of all glycoproteins and glycolipids on the surface of mammalian cells is normally sialic acid, and addition of this negatively charged residue is known as "sialylation," whereas removal by sialidases is known as "desialylation." High sialylation of the neuronal cell surface inhibits microglial phagocytosis of such neurons, via: (i) activating sialic acid receptors (Siglecs) on microglia that inhibit phagocytosis and (ii) inhibiting binding of opsonins C1q, C3, and galectin-3. Microglial sialylation inhibits inflammatory activation of microglia via: (i) activating Siglec receptors CD22 and CD33 on microglia that inhibit phagocytosis and (ii) inhibiting Toll-like receptor 4 (TLR4), complement receptor 3 (CR3), and other microglial receptors. When activated, microglia release a sialidase activity that desialylates both microglia and neurons, activating the microglia and rendering the neurons susceptible to phagocytosis. Activated microglia also release galectin-3 (Gal-3), which: (i) further activates microglia via binding to TLR4 and TREM2, (ii) binds to desialylated neurons opsonizing them for phagocytosis via Mer tyrosine kinase, and (iii) promotes Aβ aggregation and toxicity . Gal-3 and desialylation may increase in a variety of brain pathologies. Thus, Gal-3 and sialidases are potential treatment targets to prevent neuroinflammation and neurodegeneration.

Citing Articles

Inactivation of the CMAH gene and deficiency of Neu5Gc play a role in human brain evolution.

Liu Y, Li J, Liu Q Inflamm Regen. 2025; 45(1):5.

PMID: 39920734 PMC: 11806805. DOI: 10.1186/s41232-025-00368-3.


Delta-opioid receptor signaling alleviates neuropathology and cognitive impairment in the mouse model of Alzheimer's disease by regulating microglia homeostasis and inhibiting HMGB1 pathway.

Xu Y, Shao N, Zhi F, Chen R, Yang Y, Li J Alzheimers Res Ther. 2025; 17(1):35.

PMID: 39893485 PMC: 11786345. DOI: 10.1186/s13195-025-01682-1.


Hyperhomocysteinemia-induced VCID results in visual deficits, reduced neuroinflammation and vascular alterations in the retina.

Weekman E, Rogers C, Sudduth T, Wilcock D J Neuroinflammation. 2025; 22(1):23.

PMID: 39885592 PMC: 11783940. DOI: 10.1186/s12974-025-03332-7.


Development and validation of Galectin-3 and CVAI-based model for predicting cognitive impairment in type 2 diabetes.

Zhou X, Dai N, Yu D, Niu T, Wang S J Endocrinol Invest. 2024; .

PMID: 39565520 DOI: 10.1007/s40618-024-02506-z.


Biological function of sialic acid and sialylation in human health and disease.

Zhu W, Zhou Y, Guo L, Feng S Cell Death Discov. 2024; 10(1):415.

PMID: 39349440 PMC: 11442784. DOI: 10.1038/s41420-024-02180-3.


References
1.
Davies L, Varki A . Why Is N-Glycolylneuraminic Acid Rare in the Vertebrate Brain?. Top Curr Chem. 2013; 366:31-54. PMC: 4026345. DOI: 10.1007/128_2013_419. View

2.
Miyagi T, Yamaguchi K . Mammalian sialidases: physiological and pathological roles in cellular functions. Glycobiology. 2012; 22(7):880-96. DOI: 10.1093/glycob/cws057. View

3.
Sato C, Kitajima K . Impact of structural aberrancy of polysialic acid and its synthetic enzyme ST8SIA2 in schizophrenia. Front Cell Neurosci. 2013; 7:61. PMC: 3646324. DOI: 10.3389/fncel.2013.00061. View

4.
Griciuc A, Serrano-Pozo A, Parrado A, Lesinski A, Asselin C, Mullin K . Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013; 78(4):631-43. PMC: 3706457. DOI: 10.1016/j.neuron.2013.04.014. View

5.
Naj A, Jun G, Beecham G, Wang L, Vardarajan B, Buros J . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011; 43(5):436-41. PMC: 3090745. DOI: 10.1038/ng.801. View